{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T20:54:34Z","timestamp":1648760074802},"reference-count":28,"publisher":"Akademiai Kiado Zrt.","issue":"41","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orvosi Hetilap"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:p>Introduction: Treatment of immune thrombocytopenia is sometimes difficult and needs personal setting. According to evidence-based guidelines, corticosteroids are suggested for first-line treatment. In case of corticosteroid ineffectiveness, second-line therapeutic options (splenectomy, immunosuppressive drugs and, recently, thrombopoietin-mimetics) may result in beneficial therapeutic effect. Aims: The aim of the authors was to examine the clinicopathological data, disease course, treatment results, and the effectiveness of novel drugs in patients with immune thrombocytopenia. Patients and methods: The authors retrospectively analysed the files of 79 immune thrombocytopenic patients (26 males and 53 females) diagnosed and treated at the hematologic in- and outpatient units of the Markusovszky Hospital, County Vas, Hungary between January 1, 2000 and December 31, 2011. Remission rates, disease-free and overall survivals in response to corticosteroids (first-line treatment), after splenectomy (in cases when corticosteroids proved to be ineffective) and following second-line treatment were analysed. Survival curves were constructed using statistical software programs. Results: Of the 79 patients during a median follow-up of 66 months (min. 3, max. 144 months), 28 patients receiving first-line corticosteroids achieved complete remission and remained in a prolonged disease-free condition (35.4%; median disease-free survival 75.5 months; min. 2, max. 140 months). Thirty-eight patients underwent splenectomy after ineffective treatment with corticosteroids or other immunosuppressive (48.0%; median disease-free survival 94.2 months; min. 6, max. 136 months). Surgical complications occurred in 2 cases, while postoperative and late infections were absent. Five patients died but death was not related to immune thrombocytemia. Second-line treatment was applied in 13 patients (16.4%) and among these patients relapse of immune thrombocytopenia after splenectomy was observed in 6 patients. Favourable effects of both conventional (immunosuppressive) and novel treatments (rituximab, thrombopoietin-mimetics) were also detected. Conclusions: More than two-thirds of patients with immune thrombocytopenia responded to corticosteroids or to splenectomy and achieved prolonged disease-free remission. Novel drugs (rituximab, thrombopoietin-mimetics) applied only in few cases produced also favourable results in patients not responding to corticosteroids and splenectomy. Orv. Hetil., 2012, 153, 1613\u20131621.<\/jats:p>","DOI":"10.1556\/oh.2012.29456","type":"journal-article","created":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T01:01:45Z","timestamp":1349744505000},"page":"1613-1621","source":"Crossref","is-referenced-by-count":0,"title":["Treatment outcome of immune thrombocytopenia"],"prefix":"10.1556","volume":"153","author":[{"given":"J\u00e1nos L\u00e1szl\u00f3","family":"Iv\u00e1nyi","sequence":"first","affiliation":[{"name":"Vas Megyei Markusovszky K\u00f3rh\u00e1z, Egyetemi Oktat\u00f3k\u00f3rh\u00e1z Nonprofit Zrt. Haematologiai \u00e9s Haemostaseologiai Oszt\u00e1ly Szombathely Markusovszky L. u. 5. 9700"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9va","family":"Marton","sequence":"additional","affiliation":[{"name":"Vas Megyei Markusovszky K\u00f3rh\u00e1z, Egyetemi Oktat\u00f3k\u00f3rh\u00e1z Nonprofit Zrt. Haematologiai \u00e9s Haemostaseologiai Oszt\u00e1ly Szombathely Markusovszky L. u. 5. 9700"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rk","family":"Plander","sequence":"additional","affiliation":[{"name":"Vas Megyei Markusovszky K\u00f3rh\u00e1z, Egyetemi Oktat\u00f3k\u00f3rh\u00e1z Nonprofit Zrt. Haematologiai \u00e9s Haemostaseologiai Oszt\u00e1ly Szombathely Markusovszky L. u. 5. 9700"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"atypb1","first-page":"245","volume":"43","year":"2010","journal-title":"Hematol.-Transzfuziol."},{"key":"atypb2","first-page":"2331","volume":"144","year":"2003","journal-title":"Orv. Hetil."},{"key":"atypb3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V88.1.3.3","volume":"88","year":"1996","journal-title":"Blood"},{"key":"atypb4","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1046\/j.1365-2141.2003.04131.x","volume":"120","year":"2003","journal-title":"Br. J. Haematol."},{"key":"atypb5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","volume":"115","year":"2010","journal-title":"Blood"},{"key":"atypb6","first-page":"2723","volume":"142","year":"2001","journal-title":"Orv. Hetil."},{"key":"atypb7","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","year":"2009","journal-title":"Blood"},{"key":"atypb8","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","volume":"117","year":"2011","journal-title":"Blood"},{"key":"atypb9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00508-012-0123-3","volume":"124","year":"2012","journal-title":"Wien. Klin. Wochenschr."},{"key":"atypb10","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2004-12-4598","volume":"106","year":"2005","journal-title":"Blood"},{"key":"atypb11","first-page":"21","volume":"10","year":"2008","journal-title":"Focus Medicinae"},{"key":"atypb12","first-page":"131","volume":"43","year":"1990","journal-title":"Magyar Belorv. Arch."},{"key":"atypb13","volume-title":"Immune thrombocytopenia in adults. [Feln\u0151ttkori immunthrombocytopenia.]","year":"2011"},{"key":"atypb14","first-page":"175","volume":"330","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"atypb15","first-page":"27","volume":"10","year":"2008","journal-title":"Focus Medicinae"},{"key":"atypb16","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood-2005-12-015222","volume":"109","year":"2007","journal-title":"Blood"},{"key":"atypb17","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1182\/blood.V87.10.4068.bloodjournal87104068","volume":"87","year":"1996","journal-title":"Blood"},{"key":"atypb18","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","volume":"104","year":"2004","journal-title":"Blood"},{"key":"atypb19","first-page":"94","volume":"72","year":"2033","journal-title":"Am. J. Hematol."},{"key":"atypb20","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000205503","volume":"20","year":"1958","journal-title":"Acta Haematol."},{"key":"atypb21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1600-0609.2006.00665.x","volume":"77","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"atypb22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"atypb23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"atypb24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/stem.5530160719","volume":"16","year":"1998","journal-title":"Stem Cells"},{"key":"atypb25","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2007-02-068999","volume":"110","year":"2007","journal-title":"Blood"},{"key":"atypb27","first-page":"178","volume":"37","year":"2004","journal-title":"Hematol.-Transzfuziol."},{"key":"atypb28","first-page":"1791","volume":"146","year":"2005","journal-title":"Orv. Hetil."},{"key":"atypb31","first-page":"136","volume":"62","year":"2011","journal-title":"Gyermekgy\u00f3gy\u00e1szat"}],"container-title":["Orvosi Hetilap"],"original-title":[],"language":"hu","link":[{"URL":"https:\/\/www.akademiai.com\/doi\/pdf\/10.1556\/OH.2012.29456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T16:00:34Z","timestamp":1594742434000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/doi\/10.1556\/oh.2012.29456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":28,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1556\/OH.2012.29456"],"URL":"https:\/\/doi.org\/10.1556\/oh.2012.29456","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}